Oral News and Research

RSS

California Medicaid cuts spark anger; N.Y. Medicaid fraud detection

In California, doctors are blasting a decision to cut payments for caring for poor patients.

1 Nov 2011

ProPhase Labs introduces new Cold-EEZE Oral Spray

ProPhase Labs, makers of Cold-EEZE, a leader in over-the-counter (OTC) homeopathic cold remedies, continues to pioneer the category as they launch their first-ever Cold-EEZE Oral Spray. The new Oral Spray is formulated with zinc gluconate, the same effective active ingredient found in the best-selling, clinically proven and #1 pharmacist recommended Cold-EEZE lozenges.

1 Nov 2011

Pharmasset initiates PSI-7977 Phase 3 program for HCV

Pharmasset, Inc. today announced the initiation of a Phase 3 program with the hepatitis C virus (HCV) nucleotide analog, PSI-7977. This pivotal program will evaluate a 12-week, all-oral, interferon-free regimen of PSI-7977 and ribavirin in patients with HCV, independent of viral genotype or their ability to take interferon therapy.

1 Nov 2011

NPS announces new data from GATTEX Phase 3 study on short bowel syndrome

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced new data from STEPS 2, a long-term open-label study, showing that GATTEX (teduglutide) was associated with achieving and maintaining clinically meaningful reductions in parenteral nutrition (PN) and intravenous (IV) fluid volume in adult subjects with short bowel syndrome.

1 Nov 2011

JDR publishes 'MicroRNA Modulation in Obesity and Periodontitis' study

In a study titled "MicroRNA Modulation in Obesity and Periodontitis," lead author Romina Perri, University of North Carolina School of Dentistry, Oral Health Institute, conducted a pilot investigation to determine whether obesity or periodontal disease modified microRNA expression and whether there was any potential interaction between obesity and periodontitis that could involve microRNA modulation.

1 Nov 2011

Azantis introduces reduced glutathione and vitamin C liposomal products

Azantis launched today two innovative liposomal products: reduced glutathione and vitamin C. Both oral supplements are formulated in liposomal form to maximize absorption and to minimize side effects. Azantis, a leading phospholipid manufacturer, markets the liposomal products to resellers targeting the health care practitioner channel.

1 Nov 2011

'Good bugs' promising against ulcerative colitis, psoriasis, chronic fatigue syndrome

In four different studies presented at the American College of Gastroenterology's (ACG) 76th Annual Scientific meeting in Washington, DC, researchers explored the effectiveness of probiotics for antibiotic-associated diarrhea; as an anti-inflammatory agent for patients with ulcerative colitis, psoriasis and chronic fatigue syndrome; and for people with abdominal discomfort and bloating who have not been diagnosed with a functional bowel disorder, such as irritable bowel syndrome (IBS).

31 Oct 2011

J&JPRD submits NUCYNTA ER sNDA to FDA for DPN associated neuropathic pain

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that it has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration for NUCYNTA ER (tapentadol) extended-release tablets, an oral analgesic, for the management of neuropathic pain associated with diabetic peripheral neuropathy in adults.

31 Oct 2011

Positive initial results from CytRx's INNO-206 Phase 1b/2 clinical trial for advanced solid tumors

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced favorable response and safety indications from a group of patients with advanced solid tumors (principally soft tissue sarcomas) in the Company's ongoing Phase 1b/2 clinical trial with INNO-206, its tumor-targeting conjugate of the commonly used chemotherapeutic agent doxorubicin.

31 Oct 2011

Pacira's third quarter total revenues decrease to $4.0 million

Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced financial results for the third quarter ended September 30, 2011 and provided an update on the U.S. Food and Drug Administration's (FDA) approval of EXPAREL and the commercial strategy to support the product launch.

31 Oct 2011

Oral hormonal contraceptives linked to blood clots: Study

A new study has shown that women who use new type of contraceptive pills are twice as likely to develop life threatening blood clots as those who take older versions. Oral hormonal contraceptives have been known to increase the risk of a blood clot in deep leg veins, known as venous thromboembolism (VTE). These can prove fatal if they travel to the lungs. But, researchers at the University of Copenhagen, Denmark, found the “third-generation” pills are doubly harmful than the older versions.

30 Oct 2011

State highlights: Wash. Gov. announces more budget cuts

For the fourth year in a row, Gov. Chris Gregoire on Thursday outlined more than $1.5 billion in state cuts to health care, social services, prisons and education.The latest round would increase public-school class sizes, eliminate subsidized health care for the working poor and release hundreds of inmates early…. The state's Basic Health Plan would close, ending state-subsidized insurance for about 35,000 low-income people.

29 Oct 2011

ZIOPHARM reports promising preclinical data with palifosfamide in pediatric sarcoma model

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced the presentation of promising preclinical data with palifosfamide in a pediatric sarcoma model.

29 Oct 2011

White Smile Global introduces new at-home, foaming teeth whitening product

White Smile Global Inc. introduces the White Smile Complete Oral Foam featuring Dual Oxygen-Infused Technology.

29 Oct 2011

Merck third quarter global sales increase 8% to $12.0 billion

Merck, known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2011.

29 Oct 2011

Smile Brands announces opening of new Monarch Dental office in Granbury

Smile Brands Inc., the nation's leading provider of business support services to dental groups in the United States, today announced the grand opening of a new Monarch Dental office in Granbury, TX which will be the 55th in the Dallas-Fort Worth area.

29 Oct 2011

NHS must plan to deal with predicted 45% leap in new cancer cases

The NHS must start planning now to deal with a predicted leap of 45 per cent in the number of new cancer cases in the UK over the next two decades, Cancer Research UK warns today (Friday).

28 Oct 2011

Biogen Idec third quarter revenues increase 11% to $1.3 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its third quarter 2011 results.

28 Oct 2011

Study: Many older Ontarians are not visiting dentists regularly

Forty-five per cent of Ontarians 65 years and older did not see a dentist in the last year, increasing their risk of chronic diseases and a reduced quality of life , a new study by researchers at St. Michael's Hospital, Women's College Hospital and the Institute for Clinical and Evaluative Sciences (ICES) shows.

28 Oct 2011

High Court justices could decide Nov. 10 which health law cases to hear

A closed-door meeting is on the justices' schedule during which they will review petitions regarding challenges to the health law. Their decision about how - and when - to proceed could be made public as soon as Nov. 14.

28 Oct 2011